Illumina (ILMN) stock fell by 3.7%, primarily due to broader market pressures arising from the announcement of a 25% tariff on Indian imports and the associated penalties for Russian oil purchases, which signal concerns about trade dynamics and their impact on various sectors, including biotech.

Illumina (ILMN) stock fell by 3

Illumina (ILMN) stock fell by 1.89% due to concerns regarding its relative performance compared to Opus Genetics, which received more favorable ratings and higher potential upside from analysts, leading to a perception that ILMN may be less advantageous to investors at this time.

Illumina (ILMN) stock fell by 1

Illumina (ILMN) stock declined by 1.06% following a series of target price adjustments by various analysts, with the general consensus rating being "Hold," which reflects cautious sentiment in the market despite some analysts setting higher price targets.

Illumina (ILMN) stock declined by 1

Illumina, Inc. (NASDAQ: ILMN) saw a slight increase of 0.53% in its stock price due to ongoing investments from institutional investors, which suggests positive sentiment around the company's performance and outlook following a recent earnings report that surpassed analyst expectations.

Illumina, Inc

Illumina (ILMN) stock rose by 2.9% ahead of its anticipated Q2 2025 earnings report, as analysts expect positive performance with projected earnings of $1.02 per share and revenue of $1.12 billion, amidst recent insider purchasing and increased stake by a hedge fund.

Illumina (ILMN) stock rose by 2

Illumina (ILMN) stock rose 7.63% possibly in response to a mixed outlook from analysts, where some maintained buy ratings despite downgrades and price target reductions, as well as positive earnings results that exceeded expectations in the previous quarter.

Illumina (ILMN) stock rose 7

Illumina (ILMN) stock fell 1.4% due to a reduction in institutional investment, with significant institutional stake cuts, and several analysts lowering their price targets for the company.

Illumina (ILMN) stock fell 1

Illumina, Inc. (NASDAQ:ILMN) shares rose 1.0% as analysts maintain a "Hold" rating on the stock, amidst mixed updates on price targets and the company demonstrating slightly better-than-expected quarterly earnings. The stock increased likely due to the positive earnings report that exceeded analyst expectations, along with notable insider buying, suggesting confidence in the company's future.

Illumina (ILMN) stock declined by 0.2% due to broader market trends and investor sentiment, which can be influenced by various factors including economic data, interest rates, and overall market conditions.

Illumina (ILMN) stock declined by 0

Illumina (ILMN) stock fell 1.4% likely due to downward adjustments in price targets and ratings from multiple research analysts, alongside a year-over-year revenue decline reported in its latest earnings data.

Illumina (ILMN) stock declined by 1.4% following a report that Allworth Financial LP decreased its stake by 17.6% and amid multiple price target reductions from analysts, indicating ongoing bearish sentiment in the market.

Illumina (ILMN) stock fell by 0.73% after Scotiabank downgraded its rating from "sector outperform" to "sector perform," reflecting a general trend of decreased price targets from various analysts following its recent earnings report, which showed a slight revenue decline year-over-year.

Illumina (ILMN) stock fell by 0

The article primarily discusses Icahn Enterprises L.P. (IEP) and its recent financial losses, while also mentioning its increased stake in Illumina (ILMN) and other companies. 

Illumina (ILMN) stock may have gone down due to broader market factors or negative sentiment related to the company’s performance, particularly in the context of Icahn Enterprises’ reported financial struggles.

The article primarily discusses Icahn Enterprises L

Illumina (ILMN) stock decreased by 0.8%, potentially due to market reactions or investor sentiment, although the article does not provide specific reasons for this decline.

Illumina (ILMN) stock decreased by 0

Illumina (ILMN) stock declined by 1.84% due to reduced institutional holdings, with notable sell-offs from Principal Financial Group and mixed analyst ratings impacting investor sentiment.

Illumina (ILMN) stock declined by 1.84% after GAMMA Investing LLC significantly reduced its stake in the company by 73.4%, signaling possible negative investor sentiment amid mixed analyst ratings and institutional investment activities.

Illumina (ILMN) stock rose by 2.18% last night, likely due to positive market sentiment or developments related to its business operations, though specific catalysts were not detailed in the article.

Illumina (ILMN) stock experienced a 0.46% increase last night, driven by various institutional investment activities and a mixed consensus of analyst ratings regarding its future performance despite recent changes in target prices.

Illumina (ILMN) stock experienced a 0

The article discusses the NZXT N9 Z890 motherboard, highlighting its modern features, unique design, and impressive RGB lighting, while also noting some drawbacks, especially regarding fan control through software. 

Illumina (ILMN) stock's increase of 0.46% may be attributed to market optimism or positive developments relating to the company or the biotechnology sector, though specific reasons for the stock movement are not detailed in the provided text.

The article discusses the NZXT N9 Z890 motherboard, highlighting its modern features, unique design,

Illumina (ILMN) stock rose by 2.87% following significant institutional investments, including the purchase of new stakes and increased positions by various firms, alongside insider buying by the CFO, indicating strong market confidence in the company's future growth.

Illumina (ILMN) stock rose 0.65%, likely due to positive market sentiment and performance comparisons favoring its strategic partnerships with companies like CareDx, which has a strong growth potential in the diagnostic solutions sector.

Illumina (ILMN) stock rose 0

Illumina (ILMN) stock rose by 0.67% due to a significant increase in call options trading activity, with traders purchasing over 10,000 call options, indicating investor optimism about the company's prospects despite recent fluctuations in analyst ratings and performance.

Illumina (ILMN) stock rose by 0

Illumina, Inc. (ILMN) stock rose by 1.0% last night, likely driven by significant institutional buying, including new positions and increased stakes by major investors, which indicates growing confidence in the company's future performance despite recent mixed earnings reports.

Illumina (NASDAQ: ILMN) stock rose by 1.87% after Barclays raised its price target from $77.00 to $85.00, although they maintain an underweight rating, indicating a potential positive sentiment amidst mixed analyst opinions on the stock.

Illumina (NASDAQ: ILMN) stock rose by 1

Illumina (NASDAQ: ILMN) stock rose by 1.87% following an increase in institutional investment, highlighted by the State of Alaska Department of Revenue boosting its stake by 2.5%, indicating growing investor confidence in the company.

Illumina (ILMN) stock rose 1.87% following significant purchases by institutional investors, including Kentucky Retirement Systems, which acquired a new position, and substantial increases in stakes by other major investors, indicating growing confidence in the company's potential as indicated by its recent earnings report exceeding expectations despite a slight year-over-year revenue decline.

Illumina (ILMN) stock rose 1

Illumina (ILMN) stock rose 1.0% due to a mix of institutional buying interest and a recent earnings report that beat expectations, suggesting a positive outlook for the company despite a slight decline in year-over-year revenue.

Illumina, Inc. (ILMN) stock rose by 1.0% due to a bullish outlook on its strong market position in genetic sequencing, the increasing adoption of its technology for cancer detection, and an appealing valuation following recent market pressures.

Illumina (ILMN) stock rose by 0.13% following the announcement of its agreement to acquire Standard BioTools’ subsidiary, SomaLogic, for $350 million in cash, which positively impacted investor sentiment and boosted Standard BioTools’ stock.

Illumina (ILMN) stock rose 0.13% following an analyst upgrade of its price target by Canaccord Genuity, reflecting cautious optimism about potential revenue growth driven by increased clinical volume and future adoption of the NovaSeq X sequencing system.

Illumina (ILMN) stock rose by 0.88% amid mixed analyst ratings, with the average target price set at $126.94, reflecting positive investor sentiment fueled by a recent earnings beat and insider buying activity by the CFO.

Illumina (ILMN) stock rose by 3.82% likely due to positive market sentiment or recent favorable developments related to their genomic sequencing technologies, which may correlate with increased demand for genomics-related innovations, much like the ongoing genomic surveillance described in the article on Salmonella Enteritidis isolates.

Illumina (ILMN) stock rose by 3

Illumina (ILMN) stock declined by 1.36% after Yousif Capital Management and several other institutional investors reduced their stakes in the company, reflecting potential concerns about its recent performance, including a slight decrease in quarterly revenue despite earnings beating expectations.

Illumina (ILMN) stock fell by -1.36% despite a price target increase from Canaccord Genuity, primarily due to several other analysts lowering their price targets and adopting neutral ratings, reflecting cautious sentiment amidst a recent quarterly revenue decline.

Illumina (ILMN) stock fell by -1

Illumina, Inc. (ILMN) stock fell by 0.5% due to mixed signals from recent analyst ratings and research reports that suggest a cautious outlook for the company's performance, along with a slight revenue decline in their latest earnings report.

Illumina (ILMN) stock fell by 1.09% due to recent earnings results showing a slight decline in revenue year-over-year and several research firms downgrading their target prices for the company's stock.

Illumina (ILMN) stock experienced a slight decline of -0.18%, potentially due to market reactions to external factors influencing the biotech sector, including competition and regulatory developments referenced in the context of recent studies on cancer treatments that may affect investor sentiment and market outlook.

Illumina (ILMN) stock experienced a slight decline of -0

Illumina (ILMN) stock rose by 2.35% due to a generally positive market sentiment over recent developments, including advancements in technology and improved performance expectations.

Illumina (ILMN) stock rose 2.35% due to positive developments in combating antibiotic resistance, highlighted by a study on a natural antibiotic, oxydifficidin, which shows promise against multidrug-resistant Neisseria gonorrhoeae, reflecting the company's ongoing involvement in genomic research and biotechnology solutions.

Illumina (ILMN) stock rose 2

Illumina, Inc. (NASDAQ:ILMN) shares experienced a 2.35% increase, attributed to a positive earnings report which slightly surpassed analyst estimates and insights from analysts maintaining a range of ratings, including buy perspectives from several firms, despite some downgrades and mixed price targets.

Illumina (ILMN) stock decreased by -0.21% due to recent downgrades and reduced target prices from various analysts, which may indicate waning investor confidence.

Illumina (ILMN) stock decreased by -0

The article discusses the technical challenges and solutions involved in accurately emulating effects from the demo "Area5150" on the IBM 5150, focusing on the "Lake" effect that requires precise timing and interactions with the CGA hardware due to its limitations. 

Regarding Illumina (ILMN) stock, it experienced a 0.8% decline likely due to market fluctuations or investor sentiment rather than specific news on the company itself, as no direct reasons for the dip are provided in the context provided.

The article discusses the technical challenges and solutions involved in accurately emulating effect

Illumina (ILMN) stock rose by 3.44% due to the promising findings from a study highlighting the role of the AARS2-PKM2 signaling pathway in protecting cardiomyocytes from ischemic stress, which unveils potential therapeutic targets for myocardial infarction and suggests significant implications for the cardiovascular disease field.

Illumina (ILMN) stock fell by 2.6% following a downgrade in its price target by Morgan Stanley from $136.00 to $100.00, indicating diminished expectations for the company's performance.

Illumina (ILMN) stock fell by 2

Illumina (ILMN) stock fell 2.6% after reports indicated a significant reduction in holdings by Mercer Global Advisors Inc., alongside downgrades in ratings and target prices from several analysts, signaling investor concern over the company's recent performance and outlook.

Illumina (ILMN) stock fell 2

Illumina (ILMN) stock fell by 2.6% following a mixed set of analyst reports that included price target reductions and changing ratings, despite a slight earnings beat in its recent quarterly results.

Illumina (ILMN) stock increased by 7.67% following its quarterly earnings report that exceeded expectations and hints of ongoing institutional investment despite several recent price target reductions by various brokerages.

Illumina (ILMN) stock increased by 7

Illumina (ILMN) stock increased by 4.23% last night, likely due to positive investor sentiment surrounding its recent performance and the overall market dynamics as investors reassess valuations amidst ongoing geopolitical tensions and economic uncertainty.

Illumina (ILMN) stock increased by 4

Illumina (ILMN) stock rose by 4.23% due to the publication of a study revealing new insights into oncogenic mechanisms involving specific fusion genes linked to rhabdomyosarcoma, which may open avenues for targeted therapies and enhance investor confidence in biotech advancements.

Illumina (ILMN) stock rose by 4

Illumina's (ILMN) stock fell by 1.4% following a downgrade in its price target from Canaccord Genuity Group, which lowered it from $115 to $92, along with similar negative adjustments from other analysts, reflecting concerns over the company's performance and outlook.

Illumina's (ILMN) stock fell by 1

Illumina (ILMN) stock fell by 1.4% as analysts lowered their price targets and ratings following a disappointing earnings report that missed expectations, contributing to investor concerns ahead of the upcoming Q1 2025 earnings release.

Illumina (ILMN) stock declined by 1.4% due to market factors affecting investor sentiment and potential concerns over performance metrics or competitive positioning in the genomics sector.

Illumina, Inc. (NASDAQ: ILMN) saw a 0.65% increase in its stock as analysts give a consensus "Hold" recommendation while adjusting target prices, with institutional buying activity indicating potential investor confidence despite mixed earnings results. 

The stock likely went up due to a combination of institutional investment interest and the general market sentiment, despite recent downgrades on price targets from several analysts.

Illumina (ILMN) stock experienced a decline of 0.17%, influenced by increasing competition and regulatory reforms in China's pharmaceutical sector that enable faster and cheaper drug development, potentially impacting Illumina's business strategies and market standing.

Illumina (ILMN) stock experienced a decline of 0

The article discusses the recent 2.56% increase in Illumina (ILMN) stock, attributed mainly to positive outlooks on its financial performance and growth potential in the genomics market amidst ongoing advancements in technology and demand for genetic sequencing solutions.

The article discusses the recent 2

Illumina (ILMN) stock rose by 1.12% following several institutional investors, including CreativeOne Wealth LLC, significantly increasing their stakes in the company during the fourth quarter, suggesting growing confidence in Illumina's future potential amidst mixed analyst ratings and price target adjustments.

Illumina (ILMN) stock rose by 1

Illumina (ILMN) stock rose by 1.12% following a report that Representative Thomas Kean purchased shares valued between $3,003 and $45,000, which likely boosted investor confidence.

Illumina (ILMN) stock fell by 1.42% last night, likely due to market reactions to broader trends in the healthcare technology sector rather than specific negative developments for the company itself.

Illumina's (ILMN) stock fell by 1.42%, potentially due to investors favoring CareDx over Grail, as analysts believe CareDx has stronger consensus ratings and higher potential upside compared to Grail.

Illumina, Inc. (ILMN) shares fell by 0.63% as several institutional investors reduced their stakes, and analysts downgraded their ratings and price targets for the stock, indicating a bearish sentiment towards the company's future performance.

The article discusses Intel's stock reaching a critical support level, which has historically indicated strong buying interest despite recent performance struggles, but it does not mention Illumina (ILMN) stock or its reasons for a 0.37% increase. Therefore, I cannot provide the specific reason for Illumina's stock rise based on this article.

The article discusses Intel's stock reaching a critical support level, which has historically indica

Illumina (ILMN) stock saw a slight increase of 0.37% partly due to fluctuations in institutional investor holdings, including Wells Fargo decreasing its stake while other firms such as Versant Capital Management made significant increases. 

The rise in Illumina's stock can be attributed to varied actions from institutional investors and analysts adjusting their price targets, reflecting ongoing interest and investment momentum in the company despite recent mixed earnings results.

Illumina (ILMN) stock saw a slight increase of 0

Illumina (ILMN) stock fell by 6.61% to a new 52-week low following a downgrade from the Royal Bank of Canada, which lowered its price target from $128 to $112, despite maintaining an outperform rating.

Illumina (ILMN) stock fell by 6

Illumina (ILMN) stock rose by 8.53% despite Citigroup reducing its price target from $90.00 to $85.00, which indicates mixed investor sentiment buoyed by the company's average rating of "Moderate Buy" and potential for upside based on various analysts' projections.

Illumina (ILMN) stock rose by 8

Illumina (ILMN) stock saw a decline of 4.29% due to a series of negative analyst ratings and lowered price targets, reflecting concerns over its recent earnings miss and overall market sentiment.

Illumina (ILMN) stock saw a decline of 4

Illumina (ILMN) stock fell by 2.96%, primarily due to investor sentiment reflecting concerns over its recent financial performance and market dynamics.

Illumina (ILMN) stock fell by 2.96% due to a combination of analyst downgrades, including HSBC lowering its rating and price target, as well as the company's recent quarterly earnings miss, which likely dampened investor confidence.

Illumina (ILMN) stock fell by -6.67% due to investor concerns regarding the company's performance and outlook as highlighted in recent analyses of its financial results and market conditions, contributing to broader negative sentiment in the biotechnology sector.

Illumina (ILMN) stock fell by -6

Illumina (ILMN) stock fell by 1.2% after Argus reduced its price target from $170 to $100 while maintaining a Buy rating, due to challenges such as geopolitical tensions, antitrust issues, and declining product sales.

Illumina (ILMN) stock declined by 0.83% amid investor skepticism regarding the hype surrounding AI in the biotech sector, as the focus shifts from technological advancements to achieving tangible clinical outcomes and effective governance in drug development.

Illumina (ILMN) stock fell by 2.77% likely due to broader market factors or investor sentiment shifts, though specific details on the reasons for the decline were not detailed in the article provided.

Illumina (ILMN) stock was down 2.77% as analysts favor Myriad Genetics over TNF Pharmaceuticals due to stronger consensus ratings and more significant potential upside, indicating a market sentiment shift impacting Illumina's performance.

Illumina (ILMN) stock was down 2

Illumina (ILMN) stock rose 3.38% due to its inclusion among top biotech stocks to watch, alongside other firms experiencing high trading volumes, indicating positive market interest and potential investor confidence in the biotechnology sector's growth prospects.

Illumina (ILMN) stock rose 3

Illumina (ILMN) stock rose by 1.84%, partially due to a mix of broker recommendations ranging from "buy" to "hold," despite some recent downgrades affecting target prices and overall sentiment. The stock's uptick may stem from its performance relative to analysts' forecasts and institutional investor activity, as significant recent stake adjustments signify continued interest in the company.

Illumina (ILMN) stock rose by 1.84% due to positive investor sentiment, as highlighted in a recent segment of Jim Cramer's "Mad Money Lightning Round."

Illumina (ILMN) stock dipped by 0.18% due to various market pressures impacting investor sentiment and performance expectations, although the specific reasons for the decline weren't detailed in the article. 

(Note: The article provided does not specifically discuss Illumina (ILMN) stock, so only a general response based on common stock market influences was given.)

Illumina (ILMN) stock dipped by 0

Illumina (ILMN) stock experienced a minor decline of 0.18%, as the company is perceived to be facing significant challenges, leading to negative sentiment among investors.

Illumina (ILMN) stock experienced a minor decline of 0

Illumina (ILMN) stock fell by 0.18% likely due to broader market instability and fears of an economic downturn resulting from President Trump's sweeping tariffs on steel and aluminum, which have spurred retaliatory measures from major trading partners like the EU and Canada.

Illumina (ILMN) stock declined by 0.18% due to the overall destabilization of the stock market and increased economic anxiety stemming from President Trump's implementation of sweeping tariffs on steel and aluminum, which have triggered retaliatory measures from major trading partners like the EU and Canada.

Illumina (ILMN) stock dipped by 0.18% despite a reaffirmed "overweight" rating from Stephens, primarily due to concerns over its recent earnings miss and downgraded price targets from several research firms.

Illumina (ILMN) stock fell by 0.18% after Canaccord Genuity Group lowered its price target from $135 to $115, resulting in a "hold" rating, while other brokerages also issued downgrades or reduced price targets.

Illumina (ILMN) stock fell by 0.38% due to a series of downgrades from research firms that lowered their price targets and ratings on the stock following a disappointing quarterly earnings report.

Illumina (ILMN) stock was down by 1.69%, likely due to market reactions or investor sentiment that negatively affected its valuation.

Illumina (ILMN) stock was down by 1

Illumina (ILMN) stock fell by 0.75% partly due to recent downgrades from several research firms, which lowered their price targets and ratings for the company, coupled with disappointing quarterly earnings that missed analysts' expectations.

Illumina (ILMN) stock fell by 1.21% likely due to heightened concerns surrounding recent findings related to Msi2's significant role in lung adenocarcinoma, which may impact the broader biotechnology sector related to cancer research and therapy development.

Illumina (ILMN) stock declined by 1.21% to $83.96, likely influenced by the overall volatility in the biotech sector and its relatively low price-to-earnings ratio indicating bearish investor sentiment amidst significant market fluctuations.

Illumina (ILMN) stock rose by 0.94% despite multiple analysts cutting their price targets and ratings, indicating a potential market response to recent institutional investments that could reflect confidence in its long-term growth prospects.

The article discusses the Nvidia GeForce RTX 5070 graphics card, describing it as a disappointing release due to its limited performance improvements over previous models and various competing options, leading to a recommendation against its purchase. 

As for the Illumina (ILMN) stock increase of 0.82%, it might be attributed to positive investor sentiment, market conditions, or specific company developments that could have raised expectations, although the article does not provide details on the exact reasons.

The article discusses the Nvidia GeForce RTX 5070 graphics card, describing it as a disappointing re

Illumina (ILMN) stock rose by 0.82% despite challenges, including a ban by China on gene sequencing technology imports, potentially due to investor confidence or market reactions unrelated to the regulatory news.

Illumina (ILMN) stock rose by 0.82% amidst rising tariffs from the U.S. government which have sparked uncertainty in the market, potentially affecting various industries including biotech, but the specific reason for ILMN's increase was not detailed in the article.

Illumina (ILMN) stock rose 0.82% last night despite a previous decline due to China's indication that it would ban the company from importing gene-mapping products in response to U.S. tariffs. The stock's increase may be attributed to investor optimism or reactions to other market dynamics, despite the underlying pressure from geopolitical tensions.

Illumina (ILMN) stock rose by 0.82% despite a broader market decline due to increased trade tensions and tariffs because of the company's resilience during market instability and potentially positive investor sentiment about its long-term growth prospects in the biotech industry.

Illumina (ILMN) stock fell by 5.4% due to disappointing earnings results that missed analysts' expectations and a series of downward revisions in target prices from several analysts.

Illumina (ILMN) stock fell by 5

Illumina (ILMN) stock fell by 1.79% due to ongoing concerns among investors regarding its performance amid challenging market conditions and potential over-reactions to industry data, rather than any specific negative news directly related to the company.

ILMN

Latest News & Analysis